RegeneRx is developing RGN-352, an injectable solution, for the treatment of cardiac tissue damage post acute myocardial infarction. It may also be useful in additional indications where systemic administration provides a clinical benefit.

RGN-352 represents a new approach to the treatment of acute heart attacks, as there is currently no pharmaceutical agent available that has shown both myocardial salvage and angiogenic properties in at-risk myocardial tissue. More specifically, preclinical studies have identified Tβ4's ability to promote cell migration, anti-apoptosis, anti-inflammation and myocardial stem cell differentiation in the heart.

RegeneRx is currently conducting a phase I clinical trial in healthy normal subjects.

	Acute Myocardial Infarction Ischemic Stroke Ischemic Renal Disease Crohn's/Ulcerative Colitis Epidermolysis Bullosa Multiple Sclerosis